Dr Vu Truong | Founder, Chief Executive Officer and Director
Aridis Pharmaceuticals | United States

Dr Vu Truong, Founder, Chief Executive Officer and Director, Aridis Pharmaceuticals

Vu L. Truong, Ph.D.
Founder, Chief Executive Officer, and Director

Dr. Truong is a founder of Aridis and recently elected to the CEO position in 2014 after having served as the company's Chief Scientific Officer for the past 9 years. He has over 18 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to Medimmune), and Medimmune (sold to Astra Zeneca). He has a life-long interest and research experience in infectious diseases, focusing on the development of innovative human monoclonal antibodies and vaccines designed to address life threatening infections. His product development experience includes FluMist™, Synagis™ mAb, and a number of other monoclonal antibody based therapeutics. Dr. Truong is the principal architect of the Aridis technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.

Appearances:



DC Pre-congress WS day April 2 @ 09:00

Incorporating passive immunization with active immunization – The role and use mABs for infectious diseases

Should there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically? Join this workshop to understand how these treatments are increasingly combined and the role of both passive and active immunization in future.

An overview of the scientific rationale & landscape survey of antibodies in preclinical and clinical development for infectious diseases

RSV and bacterial (Sa and Pa) prophylactic monoclonals in development

Current Sa antibodies used effectively for prophylaxis

True Human™ antibody therapy against C. difficile
 

back to speakers